A Phase 3 interventional study of Iptacopan in Complement Mediated Diseases e.g. PNH, IgAN, sponsored by Novartis Pharmaceuticals. Not yet recruiting. Open to participants aged 3 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Glomerulonephritis, IGA by Novartis — 10 open to participants now, 13 under way, 8 of them phase 3. Glomerulonephritis, IGA · Novartis.
Among the 19 studies in Glomerulonephritis, IGA by Novartis, this one is the 11th largest by planned enrollment of the 15 interventional ones that give a count, is one of 6 that started in 2026, is one of 9 in phase 3, reaches primary completion later than 12 of the 12 other live ones, and was the 19th registered.
277 studies on the registry are indexed under Glomerulonephritis, IGA; 107 are open to participants now.
Browse Glomerulonephritis, IGA studies →10 of the 19 studies in Glomerulonephritis, IGA by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Australia, Israel
Ages 18+
Novartis Pharmaceuticals · Sites in United States, China, Colombia and 5 more countries
Ages 2–18
Novartis Pharmaceuticals · Sites in United States, Brazil, China and 8 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 5 more countries
Ages 2–18
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 6 more countries
Ages 18–100
By country, each count listing its studies:
Of the 69 Glomerulonephritis, IGA studies recruiting now, 40 (58%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.
This study: 3 Years to 20 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 9
First in 2018; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 62 across 221 interventional studies indexed under Glomerulonephritis, IGA.
Median enrollment 103 across the 15 interventional studies, 300 across the 3 observational. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
2 of the studies in Glomerulonephritis, IGA by Novartis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT06797518Novartis PharmaceuticalsStudy to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN | 2027-11-27 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Glomerulonephritis, IGA by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this single-arm, multicenter, Phase IIIb roll-over extension study is to assess the long-term safety, tolerability, and efficacy of iptacopan in participants with complement mediated diseases.
This is a Phase IIIb, multicenter, open-label, single-arm roll-over extension study designed to evaluate the long-term safety, tolerability, and efficacy of iptacopan in participants with complement-mediated diseases who have completed a preceding Novartis-sponsored pediatric clinical trial with iptacopan and who, in the opinion of the investigator, continue to derive clinical benefit from treatment. The study will provide post-trial access to iptacopan while continuing to collect long-term safety and efficacy data.
Eligible participants who have completed a pediatric iptacopan parent study will continue to receive open-label iptacopan in this extension study.
Treatment may continue for up to 3 years following the study last patient first visit, or until iptacopan becomes commercially available and/or reimbursed according to local post-trial access requirements, whichever occurs first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants eligible for inclusion in this study must meet all of the following criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with complement-mediated diseases who have completed a preceding Novartis-sponsored pediatric clinical trial with iptacopan and who continue to derive clinical benefit from treatment will receive open-label iptacopan. Participants \>12 years of age will receive iptacopan 200 mg twice daily, and participants aged 2 to \<12 years will receive weight-based dosing.
Drug: Iptacopan
Participants \>12 years of age will receive iptacopan 200 mg twice daily, and participants aged 2 to \<12 years will receive weight-based dosing.
Also known as: LNP023
Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number of participants with AEs, SAEs and major adverse vascular events (MAVE) including abnormal cardiovascular parameters, safety laboratory parameters and vital signs qualifying and reported as AEs.
Time frame: From Day 1 through End of Treatment (EOT)/End of Study (EOS), up to approximately 3 years
Proportion of participants maintaining stable hemoglobin levels - PNH Indication only
Proportion of participants with paroxysmal nocturnal hemoglobinuria (PNH) maintaining stable hemoglobin (Hb) levels in absence of red blood cell transfusions. Stable Hb is defined as no more than a ≥2 g/dL decrease from baseline.
Time frame: From baseline through EOT/EOS, up to approximately 3 years
Proportion of participants maintaining sustained hemoglobin levels ≥10 g/dL and ≥12 g/dL - PNH Indication only
Proportion of participants with PNH maintaining sustained hemoglobin levels ≥10 g/dL and ≥12 g/dL in the absence of red blood cell transfusions
Time frame: Yearly through EOT/EOS, up to approximately 3 years
Proportion of participants with Hb levels ≥10 g/dL and ≥12 g/dL and LDH ≤1.5 ULN - PNH Indication only
Proportion of participants with PNH achieving hemoglobin (Hb) levels ≥10 g/dL and ≥12 g/dL and lactate dehydrogenase (LDH) ≤1.5 times the upper limit of normal (ULN).
Time frame: From Day 1 through EOT/EOS, up to approximately 3 years
Rate of Breakthrough Hemolysis - PNH Indication only
Breakthrough hemolysis events in participants with paroxysmal nocturnal hemoglobinuria (PNH). Clinical breakthrough hemolysis is defined based on protocol-specified clinical and laboratory criteria, including evidence of intravascular hemolysis and associated clinical signs/symptoms. The endpoint will be summarized as occurrences per year
Time frame: From baseline through End of Treatment/End of Study (up to approximately 3 years)
Log-transformed ratio to baseline in Urinary Protein-to-Creatinine Ratio (UPCR) - IgAN indication only
Log-transformed ratio to baseline in UPCR measured using first morning void (FMV) urine samples in participants with immunoglobulin A nephropathy (IgAN).
Time frame: Baseline and up to approximately 3 years
Change from baseline in estimated Glomerular Filtration Rate (eGFR) - IgAN indication only
Change from baseline in estimated glomerular filtration rate (eGFR) in participants with IgAN.
Time frame: Baseline and up to approximately 3 years
Proportion of participants achieving UPCR <0.5 g/g - IgAN indication only
Proportion of participants with IgAN achieving urinary protein-to-creatinine ratio (UPCR) \<0.5 g/g.
Time frame: At EOT/EOS, up to approximately 3 years
No study locations are listed for this record.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2032, 72 months later.
Of 27 phase 3 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 70. This study's planned 72 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.